PON2 and acute lymphoblastic leukemia: A study deployed CRISPR-Cas9 to delete PON2 in B-cell lymphoblastic leukaemia (B-ALL) models, where PON2 loss disrupted cell cycle regulation and delayed cell proliferation and discovered that high PON2 levels had been linked with poor survival in paediatric B-ALL (Pan et al. 2021).